

## Библиография к тематическому выпуску 2/2014 «Терапия шизофрении»

- Abhijnhan A, Adams CE, David A, Ozbilen M. 2007. Depot fluspirilene for schizophrenia. *Cochrane Database Syst Rev* CD001718.
- Adams CE, Fenton MK, Quraishi S, David AS. 2001. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. *Br J Psychiatry* 179:290–299.
- Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. 2009. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. *J Psychopharmacol* 23:157–162.
- Alabed S, Latifeh Y, Mohammad HA, Rifai A. 2011. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000203.
- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120:1640–1645.
- Alper K, Schwartz KA, Kolts RL, Khan A. 2007. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. *Biol Psychiatry* 62:345–354.
- Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. 2011. Onset of efficacy with acute long-acting injectable paliperidone treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. *Ann Gen Psychiatry* 10:12.
- Altamura AC, Glick ID. 2010. Designing outcome studies to determine efficacy and safety of antipsychotics for 'real world' treatment of schizophrenia. *Int J Neuropsychopharmacol* 13:971–973.
- Ananth J, Venkatesh R, Burgoyne K, Gadasalli R, Binford R, Gunatilake S. 2004. Atypical antipsychotic induced weight gain: pathophysiology and management. *Ann Clin Psychiatry* 16:75–85.
- Anghelescu I, Klawe C, Benkert O. 2000. Orlistat in the treatment of psychopharmacologically induced weight gain. *J Clin Psychopharmacol* 20:716–717.
- APA. 1997. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. *Am J Psychiatry* 154:1–63.
- APA. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. *J Clin Psychiatry* 65: 267–272.
- Arman S, Sadramely MR, Nadi M, Koleini N. 2008. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. *Saudi Med J* 29: 1130–1134.
- Atmaca M, Kuloglu M, Tezcan E, Ustundag B. 2003. Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain. *Hum Psychopharmacol* 18:457–461.
- Atmaca M, Kologlu M, Tezcan E, Ustundag B, Kilic N. 2004. Nizatidine for the treatment of patients with quetiapine-induced weight gain. *Hum Psychopharmacol* 19:37–40.
- Awad AG, Voruganti LN. 2004. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. *CNS Drugs* 18:877–893.
- Baandrup L, Gasse C, Jensen VD, Glenthøj BY, Nordentoft M, Lublin H, et al. 2010. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. *J Clin Psychiatry* 71:103–108.
- Bai YM, Yu SC, Lin CC. 2003. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 64:1342–1348.
- Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. 2005. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. *Int Clin Psychopharmacol* 20: 79–85.
- BaiYM,ChenTT,WuB,HungCH,LinWK,HuTM,etal.2006. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. *Pharmacopsychiatry* 39:135–141.
- Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, et al. 2007. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. *J Clin Psychiatry* 68:1218–1225.
- Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. 2008a. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. *World J Biol Psychiatry* 9:248–312.

- Bandelow B, Zohar J, Kasper S, Moller HJ. 2008b. How to grade categories of evidence. *World J Biol Psychiatry* 9:242–247.
- Baptista T, Hernandez L, Prieto LA, Boyero EC, de Mendoza S. 2001. Metformin in obesity associated with antipsychotic drug administration: a pilot study. *J Clin Psychiatry* 62:653–655.
- Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo- controlled trial. *Can J Psychiatry* 51:192–196.
- Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcategui E, et al. 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. *Schizophr Res* 93:99–108.
- Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al. 2008. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. *Psychiatry Res* 159:250–253.
- Baptista T, Rangel N, El Fakih Y, Uzcategui E, Galeazzi T, Beaulieu S, et al. 2009. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. *Pharmacopsychiatry* 42:14–19.
- Barinas-Mitchell E, Kuller LH, Pietropaolo S, Zhang YJ, Henderson T, Pietropaolo M. 2006. The prevalence of the 65-kilodalton isoform of glutamic acid decarboxylase autoantibodies by glucose tolerance status in elderly patients from the cardiovascular health study. *J Clin Endocrinol Metab* 91:2871–2877.
- Bassitt DP, Louza Neto MR. 1998. Clozapine efficacy in tardive dyskinesia in schizophrenic patients. *Eur Arch Psychiatry Clin Neurosci* 248:209–211.
- Bhoopathi PS, Soares-Weiser K. 2006. Benzodiazepines for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* 3: CD000205.
- Birt J. 2003. Management of weight gain associated with antipsychotics. *Ann Clin Psychiatry* 15:49–58.
- Bliesener N, Yokosoglu H, Quednow BB, Klingmuller D, Kuhn KU. 2004. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. *Pharmacopsychiatry* 37:189–191.
- Bollini P, Pampallona S, Orza MJ, Adams ME, Chalmers TC. 1994. Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials. *Psychol Med* 24:307–316.
- Borba CP, Fan X, Copeland PM, Paiva A, Freudenreich O, Henderson DC. 2011. Placebo-controlled pilot study of rimonabant for adiposity and lipids in patients with schizophrenia. *J Clin Psychopharmacol* 31:653–658.
- Bradford DW, Perkins DO, Lieberman JA. 2003. Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. *Drugs* 63:2265–2283.
- Buchanan RW. 1995. Clozapine: efficacy and safety. *Schizophr Bull* 21:579–591.
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. 2010. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 36:71–93.
- Bustillo JR, Lauriello J, Parker K, Hammond R, Rowland L, Bogenschutz M, et al. 2003. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. *Neuropsychopharmacology* 28:527–529.
- Caroff SN, Mann SC. 1988. Neuroleptic malignant syndrome. *Psychopharmacol Bull* 24:25–29.
- Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, et al. 2011. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. *J Clin Psychiatry* 72:295–303.
- Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Breier AF. 1999. Diazepam treatment of early signs of exacerbation in schizophrenia. *Am J Psychiatry* 156:299–303.
- Carriere P, Bonhomme D, Lemperiere T. 2000. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). *Eur Psychiatry* 15:321–329.
- Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. 2003. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. *Psychopharmacology (Berlin)* 166:391–399.
- Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. 2004. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. *J Clin Psychiatry* 65:187–190.
- Cavazzoni P, Tanaka Y, Roychowdhury SM, Breier A, Allison DB. 2003. Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial. *Eur Neuropsychopharmacol* 13:81–85.

- Centorrino F, Wurtman JJ, Duca KA, Fellman VH, Fogarty KV, Berry JM, et al. 2006. Weight loss in overweight patients maintained on atypical antipsychotic agents. *Int J Obes (London)* 30:1011–1016.
- Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. 2008. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. *Prog Neuropsychopharmacol Biol Psychiatry* 32:925–931.
- Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al. 2010. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. *BMJ* 341:c4024.
- Cheung HK. 1981. Schizophrenics fully remitted on neuroleptics for 3–5 years – to stop or continue drugs? *Br J Psychiatry* 138:490–494.
- Chue P, Eerdeken M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. 2005. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. *Eur Neuropsychopharmacol* 15:111–117.
- Ciliberto N, Bossie CA, Urioste R, Lasser RA. 2005. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. *Int Clin Psychopharmacol* 20:207–212.
- Citrome L. 2009. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. *Int J Clin Pract* 63: 140–150.
- Citrome L. 2010. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. *Int J Clin Pract* 64:216–239.
- Colonna L, Saleem P, Dondey-Nouvel L, Rein W. 2000. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. *Int Clin Psychopharmacol* 15:13–22.
- Cookson IB. 1987. The effects of a 50% reduction of cis(z)- flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. *Int Clin Psychopharmacol* 2:141–149.
- Correa N, Opler LA, Kay SR, Birmaher B. 1987. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. *J Clin Psychopharmacol* 7:91–95.
- Correll CU, Schenk EM. 2008. Tardive dyskinesia and new antipsychotics. *Curr Opin Psychiatry* 21:151–156.
- Cortese L, Caligiuri MP, Williams R, Schieldrop P, Manchanda R, Malla A, et al. 2008. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. *J Clin Psychopharmacol* 28:69–73.
- Cramer JA, Rosenheck R. 1998. Compliance with medication regimens for mental and physical disorders. *Psychiatr Serv* 49:196–201.
- Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, et al. 2010. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. *Eur Neuropsychopharmacol* 20:829–838.
- Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. 1986. A randomised controlled trial of prophylactic neuroleptic treatment. *Br J Psychiatry* 148:120–127.
- Csernansky JG, Mahmoud R, Brenner R. 2002. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. *New Engl J Med* 346:16–22.
- David A, Adams CE, Eisenbruch M, Quraishi S, Rathbone J. 2005. Depot fluphenazine decanoate and enanthate for schizophrenia. *Cochrane Database Syst Rev* CD000307.
- Davis JM. 1975. Overview: maintenance therapy in psychiatry: I. Schizophrenia. *Am J Psychiatry* 132:1237–1245.
- Davis JM. 1985. Maintenance therapy and the natural course of schizophrenia. *J Clin Psychiatry* 46:18–21.
- Davis JM, Chen N. 2003. Choice of maintenance medication for schizophrenia. *J Clin Psychiatry* 64(Suppl 16):24–33.
- Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, et al. 1993. Dose response of prophylactic antipsychotics. *J Clin Psychiatry* 54(Suppl):24–30.
- Davis JM, Matalon L, Watanabe MD, Blake L, Metalon L. 1994. Depot antipsychotic drugs. Place in therapy. *Drugs* 47:741–773.
- Davis JM, Chen N, Glick ID. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. *Arch Gen Psychiatry* 60:553–564.
- De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. 2006. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. *Clin Pract Epidemiol Ment Health* 2:14.

- De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, et al. 2008. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. *Schizophr Res* 101:295–303.
- De Hert M, Dekker JM, Wood D, Kahl KG, Holt RI, Moller HJ. 2009. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). *Eur Psychiatry* 24:412–424.
- De Hert M, Hudyana H, Dockx L, Bernagie C, Sweers K, Tack J, et al. 2010. Second-generation antipsychotics and constipation: a review of the literature. *Eur Psychiatry* 26: 34–44.
- De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. 2011a. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. *World Psychiatry* 10:52–77.
- De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. 2011b. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol* 8:114–126.
- Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, et al. 2005. Amantadine for weight gain associated with olanzapine treatment. *Eur Neuropsychopharmacol* 15:13–21.
- Desilets AR, Dhakal-Karki S, Dunican KC. 2008. Role of metformin for weight management in patients without type 2 diabetes. *Ann Pharmacother* 42:817–826.
- Detke HC, McDonnell DP, Brunner E, Zhao F, Sorsaburu S, Stefaniak VJ, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. *BMC Psychiatry* 10:43.
- Detke HC, Zhao F, Garhyan P, Carlson J, McDonnell D. 2011. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. *Int Clin Psychopharmacol* 26:35–42.
- Devinsky O, Honigfeld G, Patin J. 1991. Clozapine-related seizures. *Neurology* 41:369–371.
- DGPPN. 2006. S3 Praxisleitlinien in Psychiatrie und Psychotherapie. Band 1 – Behandlungsleitlinie Schizophrenie. Darmstadt: Steinkopff-Verlag.
- Dixon LB, Lehman AF, Levine J. 1995. Conventional antipsychotic medications for schizophrenia. *Schizophr Bull* 21:567–577.
- Dixon LB, Perkins B, Calmes C. 2009. Guideline Watch (September 2009): Practice Guideline for the treatment of patients with schizophrenia.
- Dupuis B, Catteau J, Dumon JP, Libert C, Petit H. 1987. Comparison of propranolol, sotalol, and betaxolol in the treatment of neuroleptic-induced akathisia. *Am J Psychiatry* 144:802–805.
- Dursun SM, Devarajan S. 2000. Clozapine weight gain, plus topiramate weight loss. *Can J Psychiatry* 45:198.
- El-Sayeh HG, Lyra da Silva JP, Rathbone J, Soares-Weiser K. 2006. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000458.
- Emsley R, Turner HJ, Schronen J, Botha K, Smit R, Oosthuizen PP. 2004. A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia. *J Clin Psychiatry* 65:696–701.
- Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. 2008. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. *Int Clin Psychopharmacol* 23:325–331.
- Essock SM, Hargreaves WA, Covell NH, Goethe J. 1996. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. *Psychopharmacol Bull* 32:683–697.
- Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. 2006. Effectiveness of switching antipsychotic medications. *Am J Psychiatry* 163:2090–2095.
- Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Moller HJ. 2005. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. *World J Biol Psychiatry* 6:132–191.
- Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Moller HJ. 2006. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry* 7:5–40.
- Farinde A. 2011. The impact of topiramate (Topamax(R)) therapy on the development of aggressive and/or agitated behavior. *J Pharm Pract* 24:568–570.

- Faulkner G, Cohn T, Remington G. 2007a. Interventions to reduce weight gain in schizophrenia. *Schizophr Bull* 33:654–656.
- Faulkner G, Cohn T, Remington G. 2007b. Interventions to reduce weight gain in schizophrenia. *Cochrane Database Syst Rev* CD005148.
- Fleischhacker WW, Roth SD, Kane JM. 1990. The pharmacologic treatment of neuroleptic-induced akathisia. *J Clin Psychopharmacol* 10:12–21.
- Fleischhacker WW, Hummer M. 1997. Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes. *Drugs* 53:915–929.
- Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. 2011. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. *Int J Neuropsychopharmacol* Jul 22:1–12. [Epub ahead of print].
- Floris M, Lejeune J, Deberdt W. 2001. Effect of amantadine on weight gain during olanzapine treatment. *Eur Neuropsychopharmacol* 11:181–182.
- Gaebel W, Janner M, Frommann N, Pietzcker A, Kopcke W, Linden M, et al. 2002. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. *Schizophr Res* 53:145–159.
- Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. 2007. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry* 68:1763–1774.
- Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. 2010. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. *Neuropsychopharmacology* 35:2367–2377.
- Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, von Wilmsdorff M, et al. 2011. Relapse prevention in first-episode schizophrenia – maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. *J Clin Psychiatry* 72:205–218.
- Ganguli R. 2007. Behavioral therapy for weight loss in patients with schizophrenia. *J Clin Psychiatry* 68(Suppl 4):19–25.
- Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. 2011. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. *Clin Schizophr Relat Psychoses* 5:75–79.
- Gilbert PL, Harris MJ, McAdams LA, Jeste DV. 1995. Neuroleptic withdrawal in schizophrenic patients. A review of the literature. *Arch Gen Psychiatry* 52:173–188.
- Glassman AH, Bigger JT Jr. 2001. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry* 158:1774–1782.
- Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, et al. 2011. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. *J Clin Psychiatry* 72:1616–1627.
- Goff DC, Hill M, Freudenreich O. 2010. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. *J Clin Psychiatry* 71(Suppl 2):20–26.
- Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphas L. 2010a. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. *Curr Med Res Opin* 26:377–387.
- Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, et al. 2010b. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. *Int Clin Psychopharmacol* 25:247–256.
- Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. 2011. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. *J Psychopharmacol* 25:685–697.
- Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. 2005. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. *Am J Psychiatry* 162:1744–1746.
- Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, et al. 2006. Olanzapine and haloperidol in first episode psychosis: two-year data. *Schizophr Res* 86:234–243.
- Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. 2011. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). *Schizophr Res* 134:187–194.

- Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. 2009. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. *World J Biol Psychiatry* 10:85–116.
- Gupta S, Masand PS, Virk S, Schwartz T, Hameed A, Frank BL, et al. 2004. Weight decline in patients switching from olanzapine to quetiapine. *Schizophr Res* 70:57–62.
- Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, et al. 2011. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. *J Clin Psychiatry* 72:1222–1228.
- Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. 1998. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. *Neuropsychopharmacology* 18:41–49.
- Hamilton SH, Edgell ET, Revicki DA, Breier A. 2000. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. *Int Clin Psychopharmacol* 15:245–255.
- Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D. 2007. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. *Eur Neuropsychopharmacol* 17:235–244.
- Harrison TS, Goa KL. 2004. Long-acting risperidone: a review of its use in schizophrenia. *CNS Drugs* 18:113–132.
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. 2012. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry* 13:318–378.
- Hay DP, Hay L, Blackwell B, Spiro HR. 1990. ECT and tardive dyskinesia. *J Geriatr Psychiatry Neurol* 3:106–109.
- Heimberg C, Gallacher F, Gurc FC, Gur RE. 1995. Diet and gender moderate clozapine-related weight gain. *Hum Psychopharmacol* 10:376–371.
- Henderson DC, Copeland PM, Daley TB, Borba CP, Cather C, Nguyen DD, et al. 2005a. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain. *Am J Psychiatry* 162:954–962.
- Henderson DC, Louie PM, Koul P, Namey L, Daley TB, Nguyen DD. 2005b. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. *Ann Clin Psychiatry* 17:95–97.
- Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, et al. 2007. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. *Acta Psychiatr Scand* 115:101–105.
- Henderson DC, Fan X, Sharma B, Copeland PM, Borba CP, Boxill R, et al. 2009. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. *Acta Psychiatr Scand* 119:457–465.
- Henderson DC, Freudenreich O, Borba CP, Wang X, Copeland PM, Macklin E, et al. 2011. Effects of modafinil on weight, glucose and lipid metabolism in clozapine-treated patients with schizophrenia. *Schizophr Res* 130:53–56.
- Hill AL, Sun B, Karagianis JL, Watson SB, McDonnell DP. 2011. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. *BMC Psychiatry* 11:28.
- Hoffmann VP, Case M, Jacobson JG. 2012. Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. *J Clin Psychiatry* 73:216–23.
- Hogarty GE, Ulrich RF. 1998. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. *J Psychiatr Res* 32:243–250.
- Hogarty GE, McEvoy JP, Munetz M, DiBarry AL, Bartone P, Cather R, et al. 1988. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. *Arch Gen Psychiatry* 45:797–805.
- Holt RI, Peveler RC. 2011. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. *Clin Endocrinol (Oxford)* 74:141–147.
- Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, et al. 2009. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 33:1022–1031.
- Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdeken M. 2010. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. *Schizophr Res* 116:107–117.

- Jean-Baptiste M, Tek C, Liskov E, Chakunta UR, Nicholls S, Hassan AQ, et al. 2007. A pilot study of a weight management program with food provision in schizophrenia. *Schizophr Res* 96:198–205.
- Jeste DV, Lacro JP, Gilbert PL, Kline J, Kline N. 1993. Treatment of late-life schizophrenia with neuroleptics. *Schizophr Bull* 19:817–830.
- Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al. 2008. Orlistat in clozapine- or olanzapine- treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 69:706–711.
- Johnson DA. 1976. The duration of maintenance therapy in chronic schizophrenia. *Acta Psychiatr Scand* 53:298–301.
- Johnson DA, Ludlow JM, Street K, Taylor RD. 1987. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. *Br J Psychiatry* 151:634–638.
- Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. 2006. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). *Arch Gen Psychiatry* 63:1079–1087.
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. 2008. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. *Lancet* 371:1085–1097.
- Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. 1982. Fluphenazine vs placebo in patients with remitted, acute first- episode schizophrenia. *Arch Gen Psychiatry* 39:70–73.
- Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, et al. 1983. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. *Arch Gen Psychiatry* 40:893–896.
- Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, et al. 2002. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. *Am J Psychiatry* 159:554–560.
- Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. *Am J Psychiatry* 160:1125–1132.
- Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. 2010. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. *Am J Psychiatry* 167:181–189.
- Kaneda Y, Kawamura I, Fujii A, Ohmori T. 2004. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. *Neuro Endocrinol Lett* 25:135–140.
- Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. 2003. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. *Int J Neuropsychopharmacol* 6:325–337.
- Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. 2006. Tardive dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. *Schizophr Res* 81:139–143.
- Keks NA, Ingham M, Khan A, Karcher K. 2007. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. *Br J Psychiatry* 191:131–139.
- Kilian R, Steinert T, Schepp W, Weiser P, Jaeger S, Pfiffner C, et al. 2012. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. *Eur Arch Psychiatry Clin Neurosci* 262:589–598.
- Kim JH, Yim SJ, Nam JH. 2006. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. *Schizophr Res* 82:115–117.
- Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, et al. 2002. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. *J Clin Psychiatry* 63:408–413.
- Kimiagar I, Dobronevsky E, Prokhorov T, Miniowitz A, Rabey JM. 2011. Rapid improvement of tardive dyskinesia with tetra- benzepam, clonazepam and clozapine combined: a naturalistic long-term follow-up study. *J Neurol* 259:660–664.
- Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. 2004. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. *Prog Neuropsychopharmacol Biol Psychiatry* 28:985–996.
- Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. 2006. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. *Psychoneuroendocrinology* 31:577–588.

- Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU. 2011. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. *Mol Psychiatry*, 18:53–66.
- Kissling W. 1991. Guidelines for neuroleptic relapse prevention in schizophrenia. Kissling W, ed. Berlin: Springer.
- Kissling W, Glue P, Medori R, Simpson S. 2007. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. *Hum Psychopharmacol* 22:505–513.
- Ko YH, Joe SH, Jung IK, Kim SH. 2005. Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain. *Clin Neuropharmacol* 28:169–175.
- Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, et al. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. *Int J Neuropsychopharmacol* 13:635–647.
- Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. 2010. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. *Schizophr Bull* 36: 94–103.
- Kumar R, Sachdev PS. 2009. Akathisia and second-generation antipsychotic drugs. *Curr Opin Psychiatry* 22:293–299.
- Kutcher S, Williamson P, MacKenzie S, Marton P, Ehrlich M. 1989. Successful clonazepam treatment of neuroleptic-induced akathisia in older adolescents and young adults: a double-blind, placebo-controlled study. *J Clin Psychopharmacol* 9:403–406.
- Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al. 2006. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. *J Clin Psychiatry* 67:1690–1697.
- Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. 2005. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. *Schizophr Res* 72:249–258.
- Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. 2008. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. *J Clin Psychiatry* 69:790–799.
- Laursen TM, Munk-Olsen T, Agerbo E, Gasse C, Mortensen PB. 2009. Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder. *Arch Gen Psychiatry* 66:713–720.
- Lee BH, Kim YK, Park SH. 2006. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. *Prog Neuropsychopharmacol Biol Psychiatry* 30:714–717.
- Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, et al. 2010. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. *Psychiatry Clin Neurosci* 64:19–27.
- Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. 2004. Practice guideline for the treatment of patients with schizophrenia, second edition. *Am J Psychiatry* 161:1–56.
- Lerner V, Bergman J, Statsenko N, Miodownik C. 2004. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 65:1550–1554.
- Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. 2003. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. *Am J Psychiatry* 160:1209–1222.
- Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. 2009a. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. *Mol Psychiatry* 14:429–447.
- Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. 2009b. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 373:31–41.
- Leucht S, Kissling W, Davis JM. 2009c. How to read and understand and use systematic reviews and meta-analyses. *Acta Psychiatr Scand* 119:443–450.
- Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. 2011a. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. *Schizophr Res* 127:83–92.
- Leucht S, Heres S, Kissling W, Davis JM. 2011b. Evidence-based pharmacotherapy of schizophrenia. *Int J Neuropsychopharmacol* 14:269–284.
- Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. 2012a. Maintenance treatment with antipsychotic drugs for schizophrenia. *Cochrane Database Syst Rev* 5:CD008016.



- Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. 2012b. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. *Lancet* 379:2063–2071.
- Leung JG, Breden EL. 2011. Tetrabenazine for the treatment of tardive dyskinesia. *Ann Pharmacother* 45:525–531.
- Li H, Rui Q, Ning X, Xu H, Gu N. 2011. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 35:1002–1008.
- Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. 1991. The effects of clozapine on tardive dyskinesia. *Br J Psychiatry* 158:503–510.
- Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. 2003. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. *Neuropsychopharmacology* 28:995–1003.
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New Engl J Med* 353:1209–1223.
- Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. 2002. Benzodiazepines for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev* CD001950.
- Lima AR, Bacaltchuk J, Barnes TR, Soares-Weiser K. 2004a. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev* CD001946.
- Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. 2004b. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev* CD003727.
- Lindenmayer JP, Khan A. 2011. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. *Schizophr Res* 125:267–277.
- Lindenmayer JP, Khan A, Eerdeken M, Van Hove I, Kushner S. 2007. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. *Eur Neuropsychopharmacol* 17:138–144.
- Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. 2003. The effects of an educational intervention on antipsychotic-induced weight gain. *J Nurs Scholarsh* 35:237–241.
- Lopez-Mato A, Rovner J, Illa G, Vieitez A, Boulosa O. 2003. [Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration]. *Vertex* 14:85–96.
- Louza MR, Bassitt DP. 2005. Maintenance treatment of severe tardive dyskinesia with clozapine: 5 years' follow-up. *J Clin Psychopharmacol* 25:180–182.
- Lu ML, Lane HY, Lin SK, Chen KP, Chang WH. 2004. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. *J Clin Psychiatry* 65:766–771.
- Lu ML, Shen WW, Chen CH. 2008. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. *Prog Neuropsychopharmacol Biol Psychiatry* 32:1978–1981.
- Lyons MK. 2011. Deep brain stimulation: current and future clinical applications. *Mayo Clin Proc* 86:662–72.
- Mahmoud R, Engelhart L, Ollendorf D, Oster G. 1999. The Risperidone Outcomes Study of Effectiveness (ROSE): a model for evaluating treatment strategies in typical psychiatric practice. *J Clin Psychiatry* 60(Suppl 3):42–47; discussion 48.
- Manu P, Sarpal D, Muir O, Kane JM, Correll CU. 2011. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. *Schizophr Res* 134:180–186.
- Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell M, Faltico G, et al. 1984. Costs and benefits of two doses of fluphenazine. *Arch Gen Psychiatry* 41:1025–1029.
- Marder SR, Glynn SM, Wirshing WC, Wirshing DA, Ross D, Widmark C, et al. 2003. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. *Am J Psychiatry* 160:1405–1412.
- Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, et al. 2004. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 161:1334–1349.
- Matsuoka I, Nakai T, Miyake M, Hirai M, Ikawa G. 1986. Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. *Jpn J Psychiatry Neurol* 40:639–646.

- Mauri M, Castrogiovanni S, Simoncini M, Iovieno N, Miniati M, Rossi A, et al. 2006. Effects of an educational intervention on weight gain in patients treated with antipsychotics. *J Clin Psychopharmacol* 26:462–466.
- McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, et al. 2010. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. *BMC Psychiatry* 10:45.
- McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, et al. 2007. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 164:1050–1060.
- Melamed E, Achiron A, Shapira A, Davidovitz S. 1991. Persistent and progressive parkinsonism after discontinuation of chronic neuroleptic therapy: an additional tardive syndrome? *Clin Neuropharmacol* 14:273–278.
- Meltzer HY, Alphas L, Green AI, Altamura AC, Anand R, Bertoldi A, et al. 2003. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 60:82–91.
- Mendhekar DN, Jiloha RC, Mehndiratta MM, War L. 2002. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. *Indian J Psychiatry* 44:387–390.
- Menza M, Vreeland B, Minsky S, Gara M, Radler DR, Sakowitz M. 2004. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. *J Clin Psychiatry* 65:471–477.
- Miller DD. 2000. Review and management of clozapine side effects. *J Clin Psychiatry* 61(Suppl 8):14–17; discussion 18–19. Miller DE, Sebastian CS. 2005. Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report. *J Clin Psychiatry* 66:269–270.
- Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, et al. 2006. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. *Clin Neuropharmacol* 29:68–72. Moller HJ. 2004. Novel antipsychotics in the long-term treatment of schizophrenia. *World J Biol Psychiatry* 5:9–19.
- Moller HJ. 2008. Do effectiveness (“real world”) studies on antipsychotics tell us the real truth? *Eur Arch Psychiatry Clin Neurosci* 258:257–270.
- Möller HJ, van Zerssen D. 1995. Course and outcome of schizophrenia. In: Hirsch SR, Weinberger DR, eds. *Schizophrenia*. Oxford:Blackwell.
- Montgomery SA, van Zwieten-Boot B. 2007. ECNP consensus meeting. Negative, depressive and cognitive symptoms of schizophrenia. Nice, March 2004. *Eur Neuropsychopharmacol* 17:70–77.
- Mukundan A, Faulkner G, Cohn T, Remington G. 2010. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. *Cochrane Database Syst Rev* CD006629.
- Muscattello MR, Bruno A, Pandolfo G, Mico U, Bellinghieri PM, Scimeca G, et al. 2011. Topiramate augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. *J Psychopharmacol* 25:667–674.
- Naber D, Lambert M. 2009. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. *CNS Drugs* 23:649–659.
- Narula PK, Rehan HS, Unni KE, Gupta N. 2010. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. *Schizophr Res* 118:218–223.
- Nasrallah HA. 2007. The case for long-acting antipsychotic agents in the post-CATIE era. *Acta Psychiatr Scand* 115:260–267. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P,
- Eerdeken M, et al. 2010. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. *Neuropsychopharmacology* 35:2072–2082.
- Newcomer JW. 2007. Metabolic syndrome and mental illness. *Am J Manag Care* 13:S170–177.
- Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, et al. 2008. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. *J Clin Psychiatry* 69:1046–1056.
- NICE. 2002. National Institute of Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance No. 54. [www.nice.org.uk](http://www.nice.org.uk).
- NICE. 2010. The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). London: The British Psychological Society.

- Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. 2011. Assessing QT interval prolongation and its associated risks with antipsychotics. *CNS Drugs* 25:473–490.
- Norgard NB, Stark JE. 2006. Olanzapine-associated neuroleptic malignant syndrome. *Pharmacotherapy* 26:1180–1182.
- Odejide OA, Aderounmu AF. 1982. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. *J Clin Psychiatry* 43:195–196.
- Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. 2009. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). *Eur Psychiatry* 24:287–296.
- Pacia SV, Devinsky O. 1994. Clozapine-related seizures: experience with 5,629 patients. *Neurology* 44:2247–2249.
- Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. 2010. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. *J Clin Psychopharmacol* 30:235–244.
- Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. 2011. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 35:218–226.
- Patel MX, Taylor M, David AS. 2009. Antipsychotic long-acting injections: mind the gap. *Br J Psychiatry Suppl* 52:S1–4.
- Pope HG Jr, Aizley HG, Keck PE Jr, McElroy SL. 1991. Neuroleptic malignant syndrome: long-term follow-up of 20 cases. *J Clin Psychiatry* 52:208–212.
- Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. 2006. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. *Schizophr Res* 85:254–265.
- Poyurovsky M, Pashinian A, Gil-Ad I, Maayan R, Schneidman M, Fuchs C, et al. 2002. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. *Am J Psychiatry* 159:1058–1060.
- Poyurovsky M, Tal V, Maayan R, Gil-Ad I, Fuchs C, Weizman A. 2004. The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. *Eur Neuropsychopharmacol* 14:332–336.
- Praharaj SK, Jana AK, Goyal N, Sinha VK. 2011. Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis. *Br J Clin Pharmacol* 71:377–382.
- Pujalte D, Bottai T, Hue B, Alric R, Pouget R, Blayac JP, et al. 1994. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. *Clin Neuropharmacol* 17:236–242.
- Purgato M, Adams CE. 2011. Bromperidol decanoate (depot) for schizophrenia. *Cochrane Database Syst Rev* 9:CD001719. Quaraishi SN, David A, Brasil MA, Alheriar FV. 1999 Depot haloperidol decanoate for schizophrenia. *Cochrane Database Syst Rev* 2004;(3):CD001719.
- Rabinowitz J, Hornik T, Davidson M. 2001. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. *J Clin Psychiatry* 62: 343–346.
- RANZCP. 2005. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *Aust NZ J Psychiatry* 39:1–30.
- Rathbone J, Soares-Weiser K. 2011. Anticholinergics for neuroleptic-induced acute akathisia. *Cochrane Database Syst Rev* CD003727.
- Resnick SG, Rosenheck RA, Canive JM, De Souza C, Stroup TS, McEvoy J, et al. 2008. Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. *J Behav Health Serv Res* 35:215–225.
- Reulbach U, Dutsch C, Biermann T, Sperling W, Thuerlauf N, Kornhuber J, et al. 2007. Managing an effective treatment for neuroleptic malignant syndrome. *Crit Care* 11:R4.
- Revicki DA, Genduso LA, Hamilton SH, Ganoczy D, Beasley CM Jr. 1999. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial. *Qual Life Res* 8:417–426.
- Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. 1999. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Arch Gen Psychiatry* 56:241–247.
- Roden DM. 2004. Drug-induced prolongation of the QT interval. *New Engl J Med* 350:1013–1022.

- Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. 1997. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *New Engl J Med* 337:809–815.
- Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R, Thomas J, et al. 1998. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *Health Serv Res* 33:1237–1261.
- Rosenheck R, Dunn L, Peszke M, Cramer J, Xu W, Thomas J, et al. 1999. Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. *Am J Psychiatry* 156:88–93.
- Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. 2003. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. *J Am Med Assoc* 290:2693–2702.
- Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. 2006. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. *Am J Psychiatry* 163: 2080–2089.
- Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. 2009. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. *Schizophr Res* 107:22–29.
- Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. *New Engl J Med* 364:842–851.
- Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. 2006. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. *Can J Psychiatry* 51:531–539.
- Sacchetti E, Guarneri L, Bravi D. 2000. H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. *Biol Psychiatry* 48:167–168.
- Sakkas P, Davis JM, Janicak PG, Wang ZY. 1991. Drug treatment of the neuroleptic malignant syndrome. *Psychopharmacol Bull* 27:381–384.
- Sako W, Goto S, Shimazu H, Murase N, Matsuzaki K, Tamura T, et al. 2008. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. *Mov Disord* 23: 1929–1931.
- Saleem P, Olie JP, Loo H. 2002. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. *Int Clin Psychopharmacol* 17:1–8.
- Sampath G, Sha A, Krska J, Soni S. 1992. Neuroleptic discontinuation in the very stable schizophrenic patient - relapse rates and serum neurolept levels. *Human Psychopharmacol Clin Exp* 7:255–264.
- Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, et al. 2005. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. *Am J Psychiatry* 162:947–953.
- Schooler NR. 1993. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis. *Br J Psychiatry Suppl* 22:58–65.
- Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. 1997. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. *Arch Gen Psychiatry* 54:453–463.
- Semple D, Smyth R. 2009. *Oxford Handbook of Psychiatry*. Oxford: Oxford University Press.
- Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. 2007. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. *Am J Psychiatry* 164:1404–1410.
- Simpson GM, Mahmoud RA, Lasser RA, Kujawa M, Bossie CA, Turkoz I, et al. 2006. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry* 67:1194–1203.
- Singh H, Levinson DF, Simpson GM, Lo ES, Friedman E. 1990. Acute dystonia during fixed-dose neuroleptic treatment. *J Clin Psychopharmacol* 10:389–396.
- Sliwa JK, Bossie CA, Ma YW, Alphs L. 2011. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. *Schizophr Res* 132:28–34.
- Soares-Weiser KV, Joy C. 2003. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000208.
- Soares KV, McGrath JJ. 2000. Anticholinergic medication for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000204.

- Soares-Weiser K, Rathbone J. 2004. Calcium channel blockers for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000206.
- Soares-Weiser K, Rathbone J. 2006. Neuroleptic reduction and/ or cessation and neuroleptics as specific treatments for tardive dyskinesia. *Cochrane Database Syst Rev* CD000459.
- Soares-Weiser K, Maayan N, McGrath J. 2011. Vitamin E for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000209.
- Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. 1997. Clozapine treatment for neuroleptic- induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. *J Clin Psychiatry* 58:318–322.
- Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, et al. 2005. Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. *Schizophr Res* 78:161–169.
- Strawn JR, Keck PE Jr, Caroff SN. 2007. Neuroleptic malignant syndrome. *Am J Psychiatry* 164:870–876.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, et al. 2006. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 163:611–622.
- Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. 2007. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. *Am J Psychiatry* 164:415–427.
- Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. 2009. Results of phase 3 of the CATIE schizophrenia trial. *Schizophr Res* 107:1–12.
- Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al. 2011. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). *Am J Psychiatry* 168:947–956.
- Stryjer R, Rosenczwaig S, Bar F, Ulman AM, Weizman A, Spivak B. 2010. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. *Clin Neuropharmacol* 33:219–222.
- Sumic JC, Baric V, Bilic P, Herceg M, Sisek-Sprem M, Jukic V. 2007. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. *Ann Gen Psychiatry* 6:13.
- Supprian T. 2004. Therapie. In: Assion HJ, Volz HP, eds. *Malgnes neuroleptisches Syndrom*. Stuttgart, New York: Thieme. p. 28–34.
- Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. 2007. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. *Am J Psychiatry* 164:428–436.
- Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M. 2012. Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. *Schizophr Res* 134:219–225.
- Tammenmaa IA, McGrath JJ, Sailas E, Soares-Weiser K. 2002. Cholinergic medication for neuroleptic-induced tardive dyskinesia. *Cochrane Database Syst Rev* CD000207.
- Tammaing CA, Thaker GK, Moran M, Kakigi T, Gao XM. 1994. Clozapine in tardive dyskinesia: observations from human and animal model studies. *J Clin Psychiatry* 55(Suppl B): 102–106.
- Tchoukhine E, Takala P, Hakko H, Raidma M, Putkonen H, Rasanen P, et al. 2011. Orlistat in clozapine- or olanzapine- treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial. *J Clin Psychiatry* 72:326–330.
- Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. 2005. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. *J Clin Psychiatry* 66:1130–1133.
- Tenback DE, van Harten PN, Slooff CJ, van Os J. 2010. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. *J Psychopharmacol* 24:1031–1035.
- Thobois S, Poisson A, Damier P. 2011. Surgery for tardive dyskinesia. *Int Rev Neurobiol* 98:289–296.
- Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvarinen S, Eronen M, et al. 2005. Topiramate add-on in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial. *J Clin Psychiatry* 66:1012–1015.
- Trollor JN, Sachdev PS. 1999. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. *Aust NZ J Psychiatry* 33:650–659.

- Trottenberg T, Volkmann J, Deuschl G, Kuhn AA, Schneider GH, Muller J, et al. 2005. Treatment of severe tardive dystonia with pallidal deep brain stimulation. *Neurology* 64:344–346.
- Ucok A, Ucok G. 1996. Maintenance ECT in a patient with catatonic schizophrenia and tardive dyskinesia. *Convuls Ther* 12:108–112.
- Umbricht D, Flury H, Bridler R. 2001. Cognitive behavior therapy for weight gain. *Am J Psychiatry* 158:971.
- Venkatasubramanian G, Arasappa R, Rao NP, Behere RV, Gangadhar BN. 2010. Adjuvant metformin worsens psychosis in schizophrenia: a case report. *Prim Care Companion J Clin Psychiatry*. 12(2). pii: PCC.09100801.
- Vinson DR, Drotts DL. 2001. Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. *Ann Emerg Med* 37:125–131.
- Voruganti L, Cortese L, Oyewumi L, Cernovsky Z, Zirul S, Awad A. 2000. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. *Schizophr Res* 43:135–145.
- Walburn J, Gray R, Gournay K, Quraishi S, David AS. 2001. Systematic review of patient and nurse attitudes to depot antipsychotic medication. *Br J Psychiatry* 179:300–307.
- Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, et al. 2010. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial. *Am J Psychiatry* 167:676–685.
- Wang Y, Turnbull I, Calne S, Stoessl AJ, Calne DB. 1997. Pallidotomy for tardive dyskinesia. *Lancet* 349:777–778.
- Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W, Schimmelmann BG, et al. 2008. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. *J Psychiatr Res* 42:676–683.
- Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. 1987. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. *Am J Psychiatry* 144:1148–1153.
- Weiden PJ, Daniel DG, Simpson G, Romano SJ. 2003a. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. *J Clin Psychopharmacol* 23:595–600.
- Weiden PJ, Simpson GM, Potkin SG, O'Sullivan RL. 2003b. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. *J Clin Psychiatry* 64:580–588.
- Weiden PJ, Kozma C, Grogg A, Locklear J. 2004. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. *Psychiatr Serv* 55:886–891.
- Weiden PJ, Newcomer JW, Loebel AD, Yang R, Lebovitz HE. 2008. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. *Neuropsychopharmacology* 33:985–994.
- Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. 2009. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. *J Clin Psychiatry* 70:1397–1406.
- Wells AJ, Sommi RW, Crismon ML. 1988. Neuroleptic challenge after neuroleptic malignant syndrome: case report and literature review. *Drug Intell Clin Pharm* 22:475–480.
- Werneke U, Taylor D, Sanders TA, Wessely S. 2003. Behavioural management of antipsychotic-induced weight gain: a review. *Acta Psychiatr Scand* 108:252–259.
- Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. 2002. The effects of novel antipsychotics on glucose and lipid levels. *J Clin Psychiatry* 63:856–865.
- Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. 2008. Metformin addition attenuates olanzapine-induced weight gain in drug-naïve first-episode schizophrenia patients: a double-blind, placebo-controlled study. *Am J Psychiatry* 165:352–358.
- Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. 2007. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. *J Clin Psychiatry* 68:654–661.
- Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, et al. 2008. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hyperprolactinemia in patients with schizophrenia. *J Clin Psychopharmacol* 28:264–370.